Gaia Grow Corp. (the “Company” or “Gaia”) (CSE:GAIA) (Frankfurt:GG0) is pleased to announce that its wholly-owned subsidiary, TruExtracts Laboratories (“TRU”), has received an amendment to its Health Canada licence that permits the company to supply extracts, edibles, and topicals directly to provincial distributors, retailers in select provinces, and licensed sellers of medical cannabis. 

Receipt of the sales amendment marks the final regulatory step required to launch sales operations of the Company's cannabis products, providing a path-to-market for anything manufactured at Tru’s facility. Tru intends to rapidly utilize the amended license to begin the process of distributing products to the Canadian market. 

This sales amendment is held in addition to its current processing and research licensing. 

"The sales amendment is a significant milestone for Tru, it allows us to monetize Tru's state of the art facility and fulfill our vision to bring top tier, unique cannabis products to the regulated market," said Frederick Pels, CEO of Gaia Grow.

"Tru is now able to generate revenue and is ultimately on the path towards sales and profitability. I look forward to updating shareholder with Tru’s progress" 

“Cannabis consumers and provincial boards are in search of innovative and high-quality products from new sources,” said Andre Sinclair, COO of Tru Extracts.

“These are exactly the types of products that are manufactured at Tru Extracts. This amendment to our licence to permit sales will allow Tru to get them to market as soon as possible."